Pretax income is the income that a company earns before paying income taxes. Enveric Biosciences's pretax income for the
three
months ended in Sep. 2024 was $-2.08 Mil.
Its pretax income for the trailing twelve months (TTM) ended in Sep. 2024 was $-9.83 Mil.
Enveric Biosciences's pretax margin was %.
During the past 13 years, Enveric Biosciences's highest Pretax Margin was -4.65%. The lowest was -24.53%. And the median was -18.05%.
Enveric Biosciences Pre-Tax Income Historical Data
The historical data trend for Enveric Biosciences's Pre-Tax Income can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Enveric Biosciences's Pre-Tax Income
For the Biotechnology subindustry, Enveric Biosciences's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Enveric Biosciences's Pre-Tax Income Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Enveric Biosciences's Pre-Tax Income distribution charts can be found below:
* The bar in red indicates where Enveric Biosciences's Pre-Tax Income falls into.
Enveric Biosciences Pre-Tax Income Calculation
This is the income that a company earns before paying income taxes.
Enveric Biosciences's Pretax Income for the fiscal year that ended in Dec. 2023 is calculated as
Pre-Tax Income for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-9.83 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enveric Biosciences (NAS:ENVB) Pre-Tax Income Explanation
Enveric Biosciences's Pretax Margin for the quarter that ended in Sep. 2024 is calculated as
During the past 13 years, Enveric Biosciences's highest Pretax Margin was -4.65%. The lowest was -24.53%. And the median was -18.05%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enveric Biosciences Pre-Tax Income Related Terms
Thank you for viewing the detailed overview of Enveric Biosciences's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.
Enveric Biosciences Inc is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders. The company's lead program, EB-003, is a first-in-class approach to the treatment of difficult-to-address mental health disorders designed to promote neuroplasticity without inducing hallucinations in the patient. Enveric is also developing EB-002, formerly EB-373, a next-generation synthetic prodrug of the active metabolite, psilocin, being studied as a treatment of psychiatric disorders.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ENVB has been successfully added to your 